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ABSTRACT 
Ngal (Neutrophil Gelatinase-associated Lipocalin ) è una proteina appartenente alla famiglia delle 
lipocaline verso cui la  recente letteratura ha mostrato  una notevole attenzione, soprattutto in 
quanto biomarcatore in alcune condizioni patologiche (danno renale acuto e cronico, patologie 
autoimmuni, neoplasie). Il ruolo biologico di NGAL non è però ancora del tutto compreso. 
Numerose sono le dimostrazioni della sua azione batteriostatica. Recenti lavori hanno inoltre 
evidenziato un ruolo di NGAL nella modulazione di NFkB. Nessun lavoro ha valutato il ruolo di 
NGAL nell’immunità umorale.  
Lo scopo dello studio è quello di capire se NGAL possa esercitare un ruolo di attivazione  
(modulazione)  della risposta T cellulare attraverso la regolazione del complesso HLA-G, un 
mediatore di tolleranza. 
Cellule mononucleate da sangue periferico (PBMCs) sono state ottenute da 8 donatori sani dopo 
consenso informato e isolate tramite centrifugazione (Ficoll). PBMC sono poi state trattate con 4 
concentrazioni crescenti di NGAL (da 40 a 320 ng/mL), associate o meno a ferro e analizzate con 
tecnica fluorimetrica ed elisa.Alle analisi eseguite NGAL stimola l’espressione di HLA-G sulle 
cellule T CD4+ con un andamento dose dipendente. L’effetto del ferro sull’espressione di HLA-G 
non è di univoca interpretazione.Inoltre L’aggiunta di NGAL in vitro modifica il pattern di 
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. In conclusione abbiamo mostrato un coinvolgimento di 
NGAL nell’immunità cellulare. Valutando il ruolo di NGAL come molecola immunomodulatoria, 
abbiamo mostrato che NGAL gioca un ruolo chiave neell’immunotolleranza aumentando 
l’espressione di HLA-G e cellule T regolatorie nei donatori sani. Un possibilAs potential future 
scenario applicativo di tale studio riguarda l’utilizzo in vivo di NGAL nell’immunomodulazione dei 




NGAL (Neutrophil Gelatinase-associated Lipocalin ) is a protein of lipocalin superfamily. Recent 
literature focused on its biomarkers function in several pathological condition (acute and chronic 
kidney damage, autoimmune disease, malignancy). NGAL biological role is not well elucidated. 
Several are the demonstration of its bacteriostatic role. Recent papers have indeed  highlight NGAL 
role in NFkB modulation. The aim of this study is to understand whether NGAL may exert a role in 
the activation (modulation) of T cell response through the regulation of HLA-G complex, a 
mediator of tolerance. 
From 8 healthy donors we obtained peripheral blood mononuclear cells (PBMCs) and we isolated 
by centrifugation on a Ficoll gradient. Cells were then treated with four concentrations of NGAL 
(40-320 ng/ml) with or without iron. We performed flow cytometry analysis and ELISA test. 
NGAL increased the HLA-G expression on CD4+ T cells, with an increasing corresponding to the 
dose. Iron effect is not of unique interpretation. NGAL adiction affects regulatory T cells increasing 






cells. Neutralizing antibody against NGAL decreased 






cells percentage.  
In conclusion, we provided in vitro evidence of NGAL involvement in cellular immunity. The 
potential role of NGAL as an immunomodulatory molecule has been evaluated: it has been shown 
that NGAL plays a pivotal  role in the induction of immune tolerance up regulating HLA-G and T 
regulatory cells expression in healthy donors. As potential future scenario we highlight the in vivo 
role of NGAL in immunology and immunomodulation, and its possible relationship with 









1.1 Neutrophil Gelatinase-associated Lipocalin (NGAL)  
Neutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein of 25 kDa molecular weight 
consisting of 198 amino acids. It owes its name to the fact that it was isolated for the first time in 
association with a gelatinase obtained from the supernatant of activated human neutrophils. Only 
later its expression was found also in other epithelial tissues including kidney, stomach, colon, 
trachea bone marrow, prostate, uterus [1,2].  
NGAL belongs to the lipocalins superfamily, that comprises a class of proteins that are 
characterized by a common secondary and tertiary structural feature— called as the "lipocalin fold". 
It is characterized by height β-strands that form a β-barrel defining a calyx. The calyx binds and 
transports low molecular weight molecules, which define the biologic activity of the lipocalin. The 
beta sheets are connected to one another by seven short loops (L1–L7), of which the loop L1 forms 
a lid-like structure to close the ligand binding cavity. The difference in specific amino acids within 
the lipocalin fold gives rise to the wide diversity in ligands that can be bound by lipocalins (Figure 
1) [3,4].  
Few examples of lipocalins are retinol-binding protein that binds and transports vitamin A [5], the 
lipocalin α1-microglobulin that scavenges heme [6], and nitrophorin-type lipocalins that carry heme 
groups complexed with nitric oxide [7]. 
Biological fluids contain very low levels of NGAL protein at steady state level. Serum contains 
approximately 20 ng/ml NGAL which is probably derived from neutrophils and from limited 
expression in liver, spleen and kidney [8]. Renal clearance is a major regulator of this steady state 
level, because circulating NGAL undergoes glomerular filtration due to its low molecular weight  
and positive charge. Theoretically, the kidney processes 3.4–4 mg NGAL per day (20 ng/ml×120–
140 ml/min glomerular filtration rate, GFR) as a result of filtration [9] followed by capture by the 
proximal tubule, where it was degraded to a 14 kDa fragment in lysosomes. Endocytosis of NGAL 
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from the apical (luminal) membrane is the most likely pathway of NGAL traffic because it appeared 
in the urine when the apical megalin receptor was deleted. Biacore based binding studies confirmed 
a direct interaction between NGAL and megalin fragments [10], consistent with capture of NGAL 
from the glomerular filtrate rather than from the basolateral (blood) side. Similar to serum, urine 
contains approximately 20 ng/ml NGAL at steady state. The origin of this protein is not clear, but 
some of it may derive from serum NGAL that bypasses capture in the proximal tubule 
(approximately 1/200 molecules). Alternatively, NGAL might derive from neutrophils or even from 
bladder epithelia. However, it is most likely that urinary NGAL derives from a low level of 
expression in the native kidney at steady state. Indeed, weak in situ RNA reactivity can be seen in 
the collecting ducts of some kidneys [11]. 
 
1.1.2 NGAL, the iron binding and the bacteriostactic action 
 In the case of NGAL, the lipophilic compound that can be tied by the lipocalin fold is represented 
by the siderophores, as demonstrated for the first time by Strong et al studies [12]. 
The estimated concentration of free iron in the body is estimated to be as low as 10−24 M) [13]. 
The exceedingly low availability of free iron is attributable to iron-binding proteins like transferrin, 
ferritin and 
lactoferrin which form complexes with any available free iron molecules. Bacteria have developed 
special proteins called siderophores that have an affinity for iron (particularly ferric iron or Fe3+) 
several times higher than that of the endogenous iron chelators. This enables siderophores to not 
only bind available free iron, but also extract iron from iron-binding proteins of the host [14].  
Goetz et al. [15,16] cloned NGAL in Gram−bacteria and identified a bacterial compound called 
enterochelin bound within the protein's calyx. Enterochelin is an organic molecule that bacteria 





Figure 1. Schematic representation of the lipocalin fold. The characteristic feature of lipocalins is the “lipocalin fold” 
which comprises of an N-terminal 3–10 helix followed by eight beta sheets. The beta sheets are connected by loops 
(L1–L7). The portion of the lipocalin fold that are structurally conserved between different lipocalins is indicated by the 
blue boxed regions while the region that shows significant conservation in amino acid sequence is indicated by the 
black boxed region [4].  
 
The interaction of enterocalin with NGAL directly blocked the capture of iron by bacteria: NGAL 
delayed bacterial growth.  Complexes of NGAL with enterocalin:Fe  could form in the bloodstream 
[17] followed by their rapid clearance by macrophages in liver and spleen and by filtration and 
tubular destruction in the kidney. Hence, the binding of enterocalin to NGAL not only sequestered 
the siderophore but resulted in its clearance in the kidney. Because NGAL levels can rise 100 fold 
to >2000 ng/ml, as much as 300–400 mg NGAL/24 h, containing nearly 1 mg of iron can 
theoretically traffic to the kidney for clearance and recycling, provided that enterocalin is fully 
saturated and glomerular filtration is maintained [11]. 
But an oversupply of iron or the expression of siderophores [18] which do not recognize NGAL, 
rescued bacterial growth. Consistently, the deletion of NGAL accelerated the growth of enterocalin 
dependent bacteria, resulting in sepsis and heightened mortality [19,20].  
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NGAL is therefore an important role in innate immune response and is expressed in particular 
tissues exposed to the external environment (and therefore susceptible to infection) as the urinary or 
the gastrointestinal tract (figure 2).  There are also many apparent differences between known 
urinary antimicrobial peptides and NGAL. For example, unlike other urinary antimicrobial proteins 
[21,22,23] the cathelicidins, the defensins [24,25], Tamm–Horsfall [26-28] and Lactoferrin [29], 
which are expressed constitutively, uNGAL  is not likely to play a large role at steady state because 
it is expressed only at very low levels (20 ng/ml). In addition, while many of these proteins are 
modulated only to a small degree by infections (cathelicidin by 3–8 fold; THP and lactoferrin are 
not stimulated by infections [30-34] and the AMPs and lactoferrin remain in the low ng/ml range 
even after stimulation), NGAL was intensively upregulated by significant infections  [35-39] as 
well as aseptic stimuli. Consequently the mechanisms of expression and induction apparently differ 
between NGAL and other antimicrobial peptides even though NGAL originates from the same cells 
as many of these proteins.  
 
1.1.3 NGAL, inflammation and oxidative stress 
The inflammatory response is a natural defense mechanisms used by the body to clear irritants and 
pathogens. NGAL has been shown to be a pro-inflammatory molecule causing some to call it a 
cytokine. [40]  Studies conducted in pulmonary inflammation (mouse models) for exemple have 
revealed that Lcn2 (the mouse equivalent of NGAL) mRNA and protein are strongly upregulated 




Figure 2 Exemple bacteriostatic action of NGAL. Gram negative bacteria (like Salmonella typhimurium) trigger an 
immune response characterized by the activation of antigen presenting cells (macrophages and dendritic cells) upon 
engulfing the bacteria. These activated cells then release cytokines like IL-18 and IL-23 that in turn activate T-
lymphocytes. These activated T-cell in turn release IL-17 and IL-22. These two cytokines act on the intestinal cells and 
stimulate the de novo synthesis of NGAL- lipocalin 2 (Lcn2). The NGAL-Lcn2 is secreted into the intestinal lumen and 
binds to bacterial iron-binding proteins (siderophores) like enterochalin. Since iron is essential for the growth of 
bacteria, the sequestration of bacterial siderophores by NGAL-Lcn2 has a bacteriostatic effect. [4]. 
 
lungs of patients with bronchial inflammation [42]. The pro-inflammatory cytokine IL-1β is able to 
induce a significant upregulation of NGAL in human lung epithelial cells [42]. This suggests a 
mechanism for upregulation of NGAL in pulmonary inflammation but its functional role in this 
process is still unclear. Several hypotheses have been proposed to explain it. One such hypothesis is 
that acute or chronic inflammation leads to the accumulation of granulocytes at the sites of 
inflammation. These granulocytes undergo apoptosis, release their granules (containing NGAL) and 
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thereby mediate local tissue injury. In support of its pro-inflammatory function, NGAL appears to 
be a chemoattractant for neutrophils [43]. 
 The importance of NGAL as an acute phase protein was demonstrated by the observation that 
following an intraperitoneal injection of E. coli, NGAL levels are elevated in the serum and in liver 
tissue within 4 h, and in the spleen within 6 h. The increase in serum levels of NGAL was preceded 
by an increase in mRNA synthesis in the peripheral blood cells. SerumNGAL levels rose by nearly 
22-fold (from 100 ng/ml to 2200 ng/ml) within 8 h following injection (of E. coli), reached a peak 
by 24 h and then gradually returned to baseline levels [44]. 
Oxidative stress can be defined as the imbalance between the prooxidant and antioxidantmachinery 
in the cell [45]. Aberrant expression of NGAL in Chinese hamster ovary (CHO) and human 
embryonic kidney (HEK293T0) cells resulted in an upregulation of the mRNA and protein levels of 
the antioxidant enzymes superoxide dismutase (SOD1 and SOD2) and heme oxygenase (HO1 and 
HO2) together with decrease in expression of NF-κB. Silencing of NGAL in A549 lung cancer cells 
had the opposite effect on HO1 and NFκB expression but increased the expression of SOD1 and 
SOD2. Further, the cells ectopically expressing NGAL were more resistant to the cytotoxic effects 
of hydrogen peroxide in vitro [46]. These results suggest that 
NGAL by inducing the expression of antioxidant enzymes helps cells counteract oxidative damage. 
Other studies have also suggested that NGAL may have a protective effect against cellular injury 
mediated by reactive oxygen species (ROS) [47].  
 
1.1.4 NGAL in kidney formation 
The normal development of urinary system has three different stages: pronephros, mesonephros, 
and metanephros. The development of metanephros, the permanent kidney, is the result of the 
expression of many genes in the cells of bud ureter and the metanephric balstema that send each 
other  messages to induce organogenesis. [Nelson, trattato di pediatria]. 
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Already at the beginning of the last century Boyden in the 1927  and later Gruenwald and Grobstein 
in the 1943 demonstrated that the stimulus to the conversion from mesenchymal cells in epithelial 
cells was given by the presence of the ureteric bud. In fact, surgical ablation of the ureteric bud 
prevented the appearance of new epithelium from metanephric blastema. [48]. 
More recent studies have shown that the gene deletion of ureteric bud obtained the same results. 
[49]. So it appeared clear that the ureteric bud provided the signals necessary for conversion of 
mesenchymal cells in epithelial cells, but the signals wasn’t known. 
In the late 1990s the Barasch and Sakuri research groups,  to reveal the identity of these factors 
have developed a line of cells of the ureteric bud that served as surrogate of the embryos ureteric 
bud [50]. These cells expressed a number of typical  ureteral bud proteins including growth factors 
and mesenchymal survival factors and receptors for factors produced by mesenchymal cells. In this 
way were isolated numerous factors each of which can stimulate the growth of metanephric 
mesenchyme and prevent its apoptosis (FGF and tissue inhibitors of metallo-proteinase) and in 
1999 also the first factor able to convert mesenchymal cells in epithelial cells (LIF, leukemia 
inhibitory factor) [51].  
Recently several other factors belongings to the complex network of signals able to synergistically 
induce mesenchymal cells into epithelial cells differentiation have been identified: FGF2, TGFβ2, 
etc [52].. In 2002 Yang et al  purified and recognized between these proteins also NGAL. [53]. 
 
1.1.5 NGAL as a growth factor 
The differentiation-inducing properties of NGAL are not limited to the embryonic kidney. 
Mounting evidence points toward growth factor effects of NGAL that modulate various cellular 
responses, such as proliferation, apoptosis, and differentiation, but this is not well understood 
mechanistically. [54].  
In a 4T1-Ras–transformed mesenchymal tumor cell line, NGAL induces markers of epithelial cells 
[55] . Furthermore, in cultured collecting duct cells, NGAL is expressed downstream of hepatocyte 
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growth factor and promotes the organization of epithelial cells into tubular structures [56] 
Antagonization of NGAL induction by expression of NGAL shRNA induces cystic structures rather 
than properly assembled tubules. Therefore, in addition to inducing epithelial characteristics in non 
epithelial cells, NGAL seems to affect the structure of established epithelia. It is interesting that 
glycodelin, another protein of the lipocalin family, displays effects on epithelial differentiation very 
similar to NGAL [57]. In vivo, NGAL protein is expressed predominantly by stimulated, growing, 
dysplastic, or involuting epithelial cells, pointing to a relevance of the in vitro observations in 
pathologic states [58]. 
Some of these effects, however, are enhanced when NGAL is associated with siderophores and 
iron, raising the possibility that in the absence of bacterial infection, endogenous molecules 
associate with NGAL to mediate its iron-binding properties. The cellular events differ strikingly—
at least in some biologic systems depending on whether NGAL is associated with iron [59].  
Cellular uptake of NGAL is followed by distribution of the protein in endosomes [60]. Different 
trafficking routes of endosomal NGAL have been proposed depending on the cell type and the 
association of NGAL with its binding partners. In kidney-derived cell lines, siderophore:iron-
associated NGAL (holo-NGAL) traffics to endosomes and releases iron from the complex, which 
results in regulation of iron-responsive genes, such as ferritin and transferrin receptor [61].  
Similarly, in the adult mouse kidney in vivo, systemically applied holo-NGAL is taken up by 
proximal tubule cells, where it delivers 55Fe [62]. The endosomal NGAL protein core is either 
degraded in lysosomes [63] or recycled to the extracellular space [64]. On the basis of these 
observations, siderophore:iron-associated NGAL is predicted to facilitate cytoplasmic iron delivery 
into target cells. A recent report suggested that the situation may be different when NGAL is 
delivered into target cells in the absence of the siderophore:iron complex. In this setting, 
NGAL is proposed to scavenge intracellular iron and exit the cell via the endosomal recycling 
pathway [65]. Therefore, at least some of the biologic effects of NGAL may depend markedly on its 
association with the siderophore:iron complex. This notion is supported by different biologic 
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responses to NGAL depending on the ligand. For instance, siderophore: iron-associated NGAL is 
more effective than apo-NGAL in inducing epithelial characteristics in 4T1-Ras–transformed 
mesenchymal tumor cells [66]. 
 
1.1.6  NGAL and pathological kidney conditions 
There is an urgent need  in clinical medicine for early predictive biomarkers of both acute kidney 
injury (AKI) and chronic kidney disease (CKD). In both situations, early intervention can 
significantly improve the prognosis. However, currently available biomarkers (such as serum 
creatinine concentrations) are imprecise, and their delayed response has impaired our ability to 
institute potentially effective therapies promptly. In recent years a series of kidney disease  
biomarker candidates were proposed both for AKI and CKD. NGAL is widely considered one of 
the most promising novel biomarkers of acute and chronic kidney damage [67].  
Several investigators have used molecular techniques such as cDNA microarrays and subtractive 
hybridizations combined with downstream proteomic analysis to identify novel pathways, 
biomarkers and drug targets in AKI. Supavekin et al. identified NGAL as one of the most 
upregulated genes in the early post-ischaemic mouse kidney [68], a finding that has now been 
confirmed in several other transcriptome profiling studies following ischaemic and nephrotoxic 
kidney injuries. Downstream proteomic studies have also revealed NGAL to be one of the earliest 
and most robustly induced proteins in the kidney after ischaemic or nephrotoxic AKI in animal 
models [69]. Importantly, NGAL protein is easily detected in the blood and urine soon after AKI in 
pre-clinical studies [70]. These findings have initiated a number of translational studies to evaluate 
NGAL as a novel biomarker in human AKI. In a cross-sectional study, subjects in the intensive care 
unit with established acute renal failure displayed a greater than 10-fold increase in plasma NGAL 
concentration and more than a 100- fold increase in urine NGAL concentration by Western blotting 
when compared to normal controls [71]. Both plasma and urine NGAL concentrations correlated 
highly with serum creatinine concentrations. Kidney biopsies in these patients showed intense 
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accumulation of immunoreactive NGAL in 50 % of the cortical tubules. These results identified 
NGAL as a widespread and sensitive response to established AKI in humans.  
NGAL has also been evaluated as a biomarker of AKI in kidney transplantation. Biopsies of 
kidneys obtained 1 h after vascular anastomosis revealed a significant correlation between NGAL 
staining intensity and the subsequent development of delayed graft function [72]. In a prospective 
multicentre study of children and adults, urine NGAL concentrations in samples collected on the 
day of transplant clearly identified cadaveric kidney recipients who subsequently developed delayed 
graft function and dialysis requirement (which typically occurred 2-4 days later). The ROC curve 
for prediction of delayed graft function based on urine NGAL concentration at day 0 showed an 
AUC of 0.9, indicative of an excellent predictive biomarker [73]. In a retrospective study of kidney 
transplant patients undergoing either protocol biopsies or clinically indicated biopsies, urine NGAL 
concentrations were found to be significantly increased in subjects with tubulitis or other tubular 
pathologies [74]. Urine NGAL also tended to be increased in subjects with subclinical tubulitis 
(p=0.06), raising the possibility of NGAL representing a non-invasive screening tool for the 
detection of tubulointerstitial disease in the early months following kidney transplantation. 
Several investigators have examined the role of NGAL as a predictive biomarker of nephrotoxicity 
following contrast administration [75]. In a prospective study of children undergoing elective 
cardiac catheterization with contrast administration, both urine and plasma NGAL predicted 
contrast-induced nephropathy (defined as a 50 % increase in serum creatinine from baseline 
concentration) within 2 h after contrast administration [76]. Using a cut-off value of 100 μg/L, the 
AUC for prediction of contrast nephropathy was excellent for the 2-h urine NGAL (0.92) as well as 
the 2-h plasma NGAL (0.91). By multivariate analysis, the 2-h NGAL concentrations in the urine 
and plasma were found to be powerful independent predictors of contrast nephropathy [77]. 
As discussed above, NGAL is a promising biomarker of AKI. In CKD, there is a growing literature 
suggesting that NGAL is also a marker of kidney disease and severity. In 45 subjects with CKD 
secondary to renal dysplasia, obstructive uropathy and glomerular and cystic diseases, plasma 
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NGAL concentrations were inversely associated with GFR [78]. As kidney function declined to <30 
mL/min, NGAL outperformed cystatin C as a biomarker of kidney failure [79]. Another study [80]  
in subjects with CKD (due to chronic glomerulone-phritis) demonstrated that mean urinary NGAL 
concentrations were higher in CKD patients (378.28 ±111.13 μg/L vs. 7.38±3.26 μg/L in controls; 
p=0.01). Furthermore, urinary NGAL concentrations were significantly correlated with serum 
creatinine concentrations (r=0.588, p-value=0.02), GFR (r=-0.528, p-value=0.04) and proteinuria 
(r=0.294, p-value=0.01) [81]. Both urine and plasma NGAL represent biomarkers of CKD severity 
in patients with autosomal dominant polycystic kidney disease [82]. In these subjects, urine and 
plasma NGAL concentrations correlated with residual GFR, and those with greater severity of 
cystic disease (measured as number of cysts >10) displayed the highest NGAL values [83].  Urine 
NGAL has also been shown to represent an early biomarker for degree of chronic tubulointerstitial 
injury in patients with IgA nephropathy [84]. 
 
1.2  IMMUNE TOLERANCE 
Immune tolerance consists of two main processes, namely central and peripheral tolerance. Central 
tolerance takes place in the thymus where most of the self-reactive T cells are deleted at an 
immature stage of their development [85]. Despite negative selection, self-reactive T cells can 
escape thymic clonal deletion, and subsequently provoke autoimmune diseases such as type 1 
diabetes (T1D), multiple sclerosis (MS), and inflammatory bowel disease (IBD) unless they are 
controlled by one of many peripheral mechanisms [86]. 
However thymic selection has been considered as an effective tolerogenic mechanism only for 
widely expressed self molecules. This assumption is based on the consideration that proteins with 
tissue-restricted expression would not be available for presentation in the thymus. Thus , tolerance 
to such proteins could only be achieved through mechanisms of peripheral tolerance. Peripheral 
tolerance mechanisms are indeed operative in extrathymic lymphoid tissues and include deletion , 
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anergy, ignorance and regulatory cells, and contribute to maintaining aotoreactive lymphocyte 
under tight control.  
Immunologic tolerance was ﬁrst introduced in 1945 when Ray Owen observed that placental 
interchange resulted in red cell chimerism between dizygotic bovine twins [87]. In the follow 
decade Medawar, McFarlane Burnet, and colleagues elaborated upon this phenomenon of acquired 
immunologic tolerance with experimental models of transplantation, which awarded them the 
Nobel Prize in Physiology or Medicine in 1960. 
Most of the work at the time involved non-self antigen exposure in immunologically immature 
hosts, until 1959 when Schwartz and Dameshek demonstrated a marked delay in the adult rabbit 
immune response to iodine-labeled injections of human serum albumin when treated with 6-
mercaptopurine [88]. Their descriptions of the inhibition of immune pathways in this “drug-induced 
immunological tolerance” notably foreshadowed the era of pharmacologic development for 
tolerance induction. 
The next 50 years heralded a boom in drug development and subsequent improvements in graft 
survival. In contrast to 1-year graft survival in 1977 of 53 and 78% for deceased and living-related 
donors, respectively [89],  modern immunosuppression has enabled transplant recipients to enjoy 
very favorable graft survival. One-year rates having asymptotically approached 93–96%; therefore, 
short-term graft survival alone can no longer be held as the metric of success for new 
immunosuppressants.  
Instead, as 10-year graft survival rates still trail at 47–61%, new agents must address factors leading 
to chronic rejection as well as the comorbidities associated with chronic immunosuppression. The 
decisive measure of success is for a therapy to demonstrate allospeciﬁc immunosuppression while 
minimizing side effects and preserving immune competence to infectious pathogens and cancer 
during drug administration, and permanent graft survival after its withdrawal. 
The understanding of the mechanisms underlying the immune tolerance of self and non self are 
essential not only for organ transplant but also in the autoimmune disease and neoplastic disease. 
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1.2.1  TOLERANCE INDUCTION 
Traditional and novel approaches to inducing tolerance in organ transplant are known:  
MOLECULE-BASED APPROACHES 
1) T CELL THERAPIES–DEPLETION 
Early attempts at transplantation in humans were fraught with early graft failure due to a robust 
alloimmuneresponse mediated by activated Tcells. We have since learned that the suppression of 
these alloreactive Tcells permits long-term graft survival and, at times, operational tolerance [90].  
Inthe1980s, [91] observed that some renal transplant patients undergoing total lymphoid irradiation 
acquired tolerance to their allografts after withdrawal of immunosuppression and demonstrated 
donor-specific unresponsiveness in vitro. Over 30years later, the concept of eliminating alloreactive 
Tcells upon induction continues to prevail, as Tcell depletion remains the most common induction 
therapy in the U.S [92] Steroids, calcineurininhibitors, rapamycin, and mycophenolatemofetil 
comprise essential components of most immunosuppressive manteinance regimens.  
Induction strategies are  instead represented by:  
- Anti-thymocyteglobulin(ATG), the oldest depleting agent dat- ing back to the late 1890s, has been 
a mainstay in induction therapy since the 1960s [93] (Due to its potency and markedly 
heterogeneous target antigen specificities, ATG is particularly useful in high-risk recipients as well 
as in preventing ischemia-reperfusion injury.  
- Alemtuzumab (Campath-1H,Genzyme),a humanized monoclonal Ab to CD52 found densely 
distributed on T and B lymphocytes  and natural killer cells [94].  
 
2) T CELLTHERAPIES–COSTIMULATIONBLOCKADE 
Alloreactive Tcell activation requires antigen-specific engagement of the Tcell receptor with major 
histocompatibility complex molecules (signal1), followed by antigen non-specific ligation of a 
variety of receptor–ligand combinations, or costimulation (signal2; JenkinsandSchwartz,1987). 
 Blockade of costimulation effectively prevents Tcell activation and allograft rejection [95].   
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While costimulation blockade renders the Tcell anergic [96], the seanergic Tcells may express 
inducible costimulator (ICOS) and play a regulatory role [97].  In addition, costimulation blockade 
does not require radical ablation of the immune system by lymphocyte depletion or irradiation, thus 
shifting the emphasis from induction to maintenance immunosuppression [98]. 
Costimulatory signals of the CD28:B7(CD80/86) immunoglobulin superfamily and 
CD40:CD154(CD40L) tumornecrosisfactor (TNF) family are the most studied and potentially most 
important activating costimulation pathways. Cytotoxiclympocyteantigen-4 (CTLA-4) shares about 
30% homology with CD28, and binds with 10–20-fold higher affinity than CD28 toB7 molecules 
on the antigen presentingcell(APC). Not only does this potently inhibit the Tcell, but also its 
ligation with APC B7 molecules induces indoleamine 2,3-dioxygenase expression, promoting the 
suppressive function sinCTLA4+ regulatoryCD4+ cells [99]. Abatacept(Orencia,Bristol-
MyersSquibb) and belatacept (Nulojix,Bristol-MyersSquibb), fusion proteins composed of CTLA-4 
and immoglobulinIgG1, have utilized this mechanism to confer potent inhibition of alloreactive 
Tcell responses.  
3) B CELLTHERAPIES  
The role of B cells in operational tolerance has yet to be defined. On one hand ,an ITN-sponsored 
collaboration identified a unique B cell signature associated with 25 operationally tolerant renal 
transplant recipients. Not only did tolerant patients exhibit an increase in total and naïve Bcells, but 
also the majority of genes that were increasingly expressed were Bcell-specific ,particularly of 
transitional Bcells [100]. While these transitional B cells could represent a regulatory B cell 
population based on their increased IL-10 production as discussed by Redfieldetal. [101]., no 
difference in B cell subsets (total, naïve, and transitional cells) or inhibitory cytokines (IL-10 and 





1.2.2  HLA-G 
 
While both HLA-A, -B, and -C class I molecules and class II molecules play an important role in 
the induction of a specific immune response by presenting peptide antigens to T cells [103] , the 
non-classical major histocompatibility complex (MHC) class I molecule HLA-G has been identified 
as a key mediator in immune tolerance [104].  It is characterized by :  
1) A tissue-restricted distribution. Whereas expression of classical HLA class I molecules is 
known to be ubiquitous, HLA-G was first described on extraembryonic trophoblast tissues 
that invade the maternal decidua during implantation of the embryo [105]. Recently, its 
expression was also reported in endothelial cells from first trimester placental chorionic 
blood vessel, in thymic epithelial cells and activated peripheral blood monocytes [106].   
2) A  limited polymorphism. Sixteen HLA-G alleles have been described to date, four of which 
may encode membrane-bound HLA-G proteins [107], plus one truncated soluble protein 
which bears the ‘delC130 mutation’ [108]; 
3) An alternative transcription of spliced messenger RNAs (mRNAs) that encode at least six 
different HLA-G isoforms, namely the HLA-G1, -G2, -G3 and -G4 membrane bound and 
HLA-G5 and -G6 soluble proteins [109].   
The “complete” HLA-G1 molecule and its soluble counterpart HLAG5 are those that have been 
studied the most. They have an identical extracellular structure, which is classic HLA class I-like: a 
heavy chain of 3 globular domains non-covalently bound to β2-microglobulin and a nonapeptide. 
The other isoforms are likely to be of simpler structure: lacking one or 2 globular domains, they are 
smaller, and should not bind β2-microglobulin and present peptides. [110]. 
Three HLA-G receptors have been described: ILT2/CD85j/LILRB1 (ILT2), ILT4/CD85d/LILRB2 
(ILT4), and KIR2DL4/CD158d (KIR2DL4) [111].   
ILT2 is expressed by B cells, some T cells, some NK cells, and all monocytes/dendritic cells, [112] 
but ILT4 is myeloid-specific and only expressed by monocytes/dendritic cells [113]. Concerning 
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KIR2DL4, its expression is mainly restricted to the CD56bright subsets of NK cells [114] which 
constitute a minority of peripheral NK cells, but a majority of uterine NK cells. [115]. Binding to 
CD8 has also been reported [116]. Through these differentially expressed receptors, HLA-G can 
interact with B cells, T cells, NK cells, and antigen-presenting cells (APC).  
Functionally, HLA-G1 inhibits the cytolytic function of uterine and peripheral blood NK cells [117] 
the antigen-specific cytolytic function of cytotoxic T lymphocytes [118] the alloproliferative 
response of CD4+ T cells [119] the proliferation of T cells and peripheral blood NK cells [120] and 
the maturation and function of dendritic cells [121].  
Soluble HLA-G5 or soluble HLA-G1, which is generated by proteasomal cleavage from the cell 
membrane, has similar functions. The other HLA-G isoforms have been less well studied, and little 
is known about their function except that membrane-bound HLA-G2, HLA-G3, and HLA-G4 can 
inhibit NK-cell and cytotoxic T lymphocyte cytolysis in vitro [122]. 
 
Table 1. HLA-G functions: Modified by Carosella Blood 2008. 
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Because of this broad inhibitory function, capable of targeting multiple immune cell subsets, much 
effort has been put into determining whether HLA-G is pathologically relevant and whether it can 
be used as a diagnostic tool or as a therapeutic tool and/or target. Transplantation and oncology are 
2 particularly clear situations. In the context of transplantation, HLA-G expression might be 
beneficial and promote tolerance to grafts. To date, the expression of HLA-G was studied in more 
than 1000 patients after heart [123]   kidney (54) liver (55) and liver-kidney(55-57) transplantation, 
with those expressing HLA-G in the graft and/or the plasma exhibiting significantly better graft 
acceptance. Thus, in transplanted patients, titration of HLA-G might be used as a monitoring tool to 
determine and follow tolerance status, which could then be used to adjust immunosuppressive 
therapies. In this context, patients with high HLA-G titers could be candidates for a reduction in 
immunosuppressive treatment, whereas HLA-G–negative patients would have a comparatively 
higher risk of rejection. Furthermore, HLA-G itself might be used as therapeutic tolerogenic agent, 
exogenously provided to HLA-G–negative patients as complementary and/or alternative therapy 
[124].  
In the context of oncology, studies on more than 1000 malignant lesions confirmed Carosellaet al 
first study on melanoma [125] which showed that HLA-G transcription and protein expression may 
be switched on in tumor lesions and protect them from NK cytolysis. It was later shown that HLA-
G expression by tumor lesions protected against cytolysis [126] correlated with malignancy in 
ovarian and breast carcinomas (61) as well as in melanocytic lesions [127] with unfavourable 
outcome in chronic lymphocytic leukemia,63 and gastric and colorectal cancers [128].  
High HLA-G plasma levels were also recently observed in patients with neuroblastoma and 
correlated with relapse[129]. Expression of HLA-G has been evidenced in several malignant 
hematopoietic diseases, particularly in acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), and B-chronic lymphocytic leukemia (B-CLL). 
Thus, HLA-G expression would favor tumor development by impairing antitumor immunity. Here 
again, HLA-G titration in peripheral blood might be used for diagnosis and/or monitoring, but in 
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this context, high titers of HLA-G would represent a negative factor [130].  In HLA-G–positive 
patients, HLA-G itself might finally constitute a therapeutic target: if expressed as a membrane-
bound protein, as observed in some hematologic malignancies [131]  HLA-G could be used as a 
tumor marker to deliver therapy. Alternatively, HLA-G could be blocked or deleted as a contributor 
to tumor immunosuppression and/or tumoral escape [132]. Recently, new aspects of HLA-G 
biology have been reported that are critical to HLA-G pathologic relevance and should help design 
HLA-G–based diagnosis and therapeutic strategies. Second is the demonstration that HLA-G is not 
only a shield against immune aggression but can also have a long-term inhibitory function through 




1.2.3 HLA-G and Regulatory T cells  
Treg cellsconstitute1–10%ofthymicandperiph- eralCD4+ T cells in human sand mice, and arise 
during athymic selection. They are characterized by the constitutive expression of the IL-2Rα 
chain(CD25) and expression of the forkhead winged helix transcriptional regulator Foxp3The 
importance of Foxp3 has been demonstrated by natural mutations of the foxp3 gene that result in a 
loss of Treg cell function and the development of severe autoimmune diseases [134]. Treg cell 
population can be divided in to the naturally occurring Foxp3 Treg population, generated in the 
thymus and anyone of many inducible Treg cell populations that are derived in the periphery 
fromCD4+Foxp3− precursors upon activation in presence of differentiating signals like TGF-β and 
IL-10 [135].  
The functional hallmark of CD4+CD25+ Treg cells is their remarkable capacity to suppress T 
effector/memory (Teff/mem) cell activation both in vitro and in vivo. Recent reviews have updated 
the idea that Tregs can regulate self-reactive T cells to maintain peripheral tolerance (non-
autoimmune recognition of organ antigens) [136]. Impaired capacity or removal of Tregs allows 
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unrestrained proliferative responses of pathogenic, autoreactive T cells. Adoptive transfer of Treg 
cells reduces the pathology of experimentally induced autoimmune diseases such as gastritis, 
insulin-dependent diabetes mellitus, and colitis [137] whereas depletion of CD4+CD25+ Treg cells 
results in the development of systemic autoimmune diseases [138]. Both the suppressive capacity 
[139] as well as the frequency of Treg cells [140] are diminished in patients with autoimmune 
diseases such as psoriasis and pemphigus vulgaris.  
So it was immediately recognized the therapeutic potential of these cells, not only in autoimmune 
disease,  but also in certain infections and tumors. The peripheral blood of epithelial cancer patients 
has elevated circulating regulatory T cells, and numerous mouse models have shown that 
manipulation of this cell population can increase or decrease immune-mediated tumor rejection 
[141]. Their tolerogenic effect also has been hypothesized to underlie the persistence of certain viral 
infections such as hepatitis C [142].  
Particular interest in their ability to determine patient tolerance to non-self antigens was augmented 
by the discovery that antigen-specific CD4+ regulatory T cells were increased in mice, which 
tolerated allografted tissues long-term [143]. A number of human studies have since shown that a 
high number of circulating TRegs in kidney and liver transplant patients is correlated with the 
stability of graft acceptance [144]. As such, considerable excitement about the clinical usage of 
TRegs in organ transplantation has been drawn up in the past decade. 
Foxp3 is considered to be a “master regulator” of the Treg lineage, and mutations or absence of the 
gene lead to a fatal, autoimmune lymphoproliferative disease in both mice and humans. [145]. The 
activation of Foxp3 itself is mediated by both acetylation and phosphorylation events [146] and the 
protein acts in complex with other transcription factors, including the nuclear factor of activated T 
cells (NFAT), to control gene expression [147].  The interaction of Foxp3 with other transcription 
factors, such as NFAT, serves to sequester these factors and thereby down-modulate expression of 
genes involved in T-cell activation and effector functions [148]. Although Foxp3 is a unique marker 
of murine Treg cells, its expression in human CD4+ T cells is not restricted to Treg cells. [149].  
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Regulatory T cells employ a variety of effector mechanisms to suppress immune responses [150] 
through both contact dependent mechanisms as well as the secretion of soluble factors. Several 
specific mechanisms have been described, including the inhibition of IL-2 secretion; release of 
inhibitory cytokines; perforin- or granzyme- dependent cytolysis of APCs or responder T cells; 
synthesis of immunosuppressive adenosine; and down-regulation of APC function via co-
stimulation with cytotoxic T-lymphocyte antigen 4 (CTLA-4, Figure 1). 
 Several studies showed that HLA-G, which is expressed by target cells, engages inhibitory 
receptors on effector cells, resulting in a transient block in their functions, and so acts as a shield 
against immune aggression [151]. However, it is now clear that HLA-G–related regulatory cells 
exist and that some of these can have a long-lasting inhibitory effect on immune responses. HLA-
G–induced regulatory T cells were first observed after stimulation of T cells with HLA-G1–
expressing APCs [152]. These regulatory T cells arise during an antigenic stimulation, do not 
respond to stimulation, and can block the alloreactivity of autologous T cells in vitro. Such 
regulatory T cells can be generated by membrane-bound HLA-G [153] or soluble HLAG5 [154]. 




As we have seen NGAL is involved in many physiological and pathological process such as iron 
delivery, bacteriostatic action, inflammation, oxidative stress and the cells growth and 
differentiation in embrional period, after tissues damage and in malignancy. The physiopathological 
link between this different action is still not well elucidated. It is not well elucidated yet if it 
participate in to the establishment of processes useful to counterbalance a condition of “aggression” 
(bacterial attack, infection disease, ischemic injury, apoptosis and necrosis), or if it’s activation 
promote, in the same conditions, regeneration process that may conduce to tissue repair or to the 
restoring physiological conditions. 
To take a step forward in the knowledge of this complex question we purpose to investigate the role 
of NGAL in  immune response modulation. 
 
In particular, we evaluated: 
1) NGAL effect on membrane-bound (mHLA-G) and soluble (sHLA-G) forms of HLA-G 
expression of  PBMNCs (in vitro model of healthy subjects) 
2) Relevance of iron presence on NGAL effects on HLA-G expression of PBMNCs 
3) NGAL effect of on T regulatory cells expression. 
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3. MATERIALS AND METHODS 
 
3.1  PBMCs isolation and cell culture 
In order to obtain cells for cell cultures, peripheral blood mononuclear cells (PBMCs) were 
obtained from 8 healthy donors after informed consent. Blood samples of 30 ml were taken in 
EDTA anticoagulant tubes. PBMCs were isolated from whole blood by Ficoll gradient (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden). and resuspended in RPMI medium (Lonza, Basel, 
Switzerland) with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 100 U/mL penicillin 
and 100 U/mL streptomycin (Sigma-Aldrich, St Louis, MO, USA). PBMCs activation was 
performed by the addition of phytohaemagglutinin, PHA (Sigma Aldrich, St. Louis, MO) 5 μg/ml 
in cell culture. 
 
3.2 NGAL in vitro effect on HLA-G expression in PBMCs 
In order to asses the in vitro effect of NGAL on HLA-G expression, PBMCs treatment was 
performed by the addition of NGAL (R&D Systems, Minneapolis, USA) conjugated with 
Enterobactin:Iron (ECM Microcollection, Tuebingen, Germany). Considering NGAL concentration  
used in Gwira’s study [156] we added to PBMC cell cultures 40 ng/ml of NGAL. Cells were 
incubated at 37° C and 5% CO2 for 72 hours. The intracytoplasmic expression of HLA-G was 
evaluated through the use of the monoclonal antibody MEMG/9-FITC (Abcam, Cambridge, UK) by 
cytometric analysis. 
To assess the expression of the following markers on PBMCs  flow cytometric analysis was made: 
CD3-PC5, CD4-PE and CD8-FITC (BD).  
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3.3 NGAL in vitro effect on HLA-G expression in PBMCs after treatment with scalar doses of 
NGAL:Enterobactin:Iron (40-320 ng/ml) 
In order to understand whether the effect of NGAL on expression of HLA-g in PBMNs was dose-
dependent, PBMCs were treated with increasing concentrations of NGAL:Enterobactin:Iron (40 
ng/ml, 80 ng/ml, 160 ng/ml and 320 ng/ml). Cells were incubated at 37° C and 5% CO2 for 72 
hours. 
The intracytoplasmic expression of mHLA-G was evaluated through the use of the monoclonal 
antibody MEMG/9-FITC (Abcam, Cambridge, UK). 
 
3.4 NGAL:Enterobactin Iron Free effect on HLA-G expression. 
In order to determinate if NGAL in vitro effect on HLA-G expression in PBMCs cultere was 
influenced by iron presence, we used NGAL  40 ng/ml conjugated with Enterobactin Iron free. 
Cells were incubated at 37° C and 5% CO2 for 72 hours. Intracytoplasmic expression of HLA-G 
was evaluated. 
 
3.5 NGAL:Enterobactin:Iron effect on HLA-G expression following anti-NGAL antibody in vitro 
administration. 
In order to evaluate if HLA-G expression depended directly by NGAL activity, Anti-NGAL 
Monoclonal Antibody (200 μg; 1 mg/ml) (Thermo Scientific, Waltham, MA, USA) was used . To 
evaluate NGAL activity inhibition we used 25 μl/ml of anti-NGAL (50 ng/ml) and 50 μl/ml of anti-
NGAL (100 ng/ml) to inhibit NGAL 40 ng/ml and 80 ng/ml respectively. 
 
3.6 Indirect evaluation of NGAL role on HLA-G expression after treatment with Enterobactin:Iron.  
PBMCs were treated only with Enterobactin:Iron (ECM Microcollection, Tuebingen, Germany)  
160 ng/ml to evaluate if HLA-G expression is directly modulated by NGAL. 
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3.7 Soluble HLA-G evaluation trough ELISA after NGAL:Enterobactin:Iron treatment. 
We evaluated sHLA-G after treatment of PBMCs with NGAL:Enterobactin:Iron 40-320 ng/ml and 
with NGAL:Enterobactin 40 ng/ml trough sHLA-G ELISA (BioVendor). 
 
3.8 NGAL effect on T regulatory cells.  
T reg Detection Kit, CD4/CD25/FoxP3-PE (Miltenyi Biotech) was used to evaluate T regulatory 
cells expression and to verify if NGAL is able to influence T regulatory cells expression after 











expression depended directly by NGAL activity, anti-NGAL Monoclonal Antibody (200 μg; 1 
mg/ml) (Thermo Scientific, Waltham, MA, USA). To evaluate NGAL activity inhibition we used 
25 μl/ml of anti-NGAL (50 ng/ml) and 50 μl/ml of anti-NGAL (100 ng/ml) to inhibit NGAL 40 
ng/ml and 80 ng/ml respectively. 










expression was dose-dependent and influenced by iron presence, PBMCs were treated with 
increasing concentrations of NGAL:Enterobactin:Iron (40 ng/ml, 80 ng/ml, 160 ng/ml and 320 
ng/ml) and NGAL:Enterobactin (40 ng/ml). Cells were incubated at 37° C and 5% CO2 for 72 
hours. 
The intracytoplasmic expression of HLA-G was evaluated through the use of the monoclonal 
antibody MEMG/9-FITC (Abcam, Cambridge, UK) by flow cytometry. The expression of CD4 and 




4.1 NGAL in vitro effect on HLA-G expression in PBMCs  
We analyzed in our research intracytoplasmic HLA-G expression on healthy donors PBMCs 
cultures. We treated PBMCs from two healthy donors with  NGAL to consider HLA-G expression 
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in the cytoplasm. After 72 hours NGAL: enterocalin:iron incubation, We observed an increase in 
HLA-G expression on CD4+. This condition is not observed for CD8+. The detection of HLA-G 
exptression with flow cytometry, was observed in not activated cells and also in cells activated with 
phytohaemagglutinin (PHA).  
Analyzing withflow cytometry PBMC cells  from healthy donors, CD4+, we notice that after 
incubation with NGAL: enterocalin: iron, there is an increase in the cells expressing HLA-G 
percentage compared to control cells. (The data regarding two of the healthy donors are presented 
in figure 3. 
 
 4.2 NGAL in vitro effect on HLA-G expression in PBMCs after treatment with scalar doses of 
NGAL:Enterobactin:Iron 
In the light of the results so far exposed, we continued our research trying different NGAL 
concentrations to understand if CD4+ and CD8+ cells  HLAG expression was dose dependent.  
We then verified  that increasing dose of NGAL:Enterobactin:Iron (40 ng/ml, 80 ng/ml, 160 ng/ml 
and 320 ng/ml ) caused an increasing HLA-G expression on CD4+ T cells using as control  PBMCs  
and activated (PBMCs trated with PHA). Figure 4.  
 
Fig. 4 HLA-G expression on CD4+ T cell: a) control PBMCs; b) PBMCs activated with PHA; c) 
PBMCs activated with PHA, treated with NGAL 40 ng\ml; d) PBMCs activated with PHA, treated 
MNCs 
CD4+ 











with NGAL 80 ng\ml; e) PBMCs activated with PHA, treated with NGAL 160 ng\ml; f) PBMCs 
activated with PHA, treated with NGAL 320 ng\ml; isotype control in black, PBMCs at different 
conditions in white. 
 
The increase was proportional to NGAL increasing concentration: in fact for subject 4 we found a 
7.3% of cell expressing HLAG in PBMCs cells, 32.8% of cell expressing HLAG in PBMCs cells 
activated with PHA, 43.8% of cell expressing HLAG with NGAL 40 ng/mL, 45.8% of cell 
expressing HLAG with NGAL 80 ng/mL, 61.8% of cell expressing HLAG with NGAL 160 ng/mL, 
67.6% of cell expressing HLAG with NGAL 320 ng/mL; in subject 5 the trend was similar: 2.8% of 
cell expressing HLAG in CD4+, 34.5% of cell expressing HLAG in CD4+ cells activated with 
PHA, 44.1% of cell expressing HLAG with NGAL 40 ng/mL, 54.6% of cell expressing HLAG with 
NGAL 80 ng/mL, 63.8% of cell expressing HLAG with NGAL 160 ng/mL, 71.9% of cell 
expressing HLAG with NGAL 320 ng/mL (figure 4)..   
The situation is different when we go to analyze CD8 + cells : in fact these cells do not exhibit a 
significant increase of the expression of HLA-G if treated with increasing concentrations of NGAL. 
These data demonstrate that HLA-G expression mediated by NGAL  shows a different trend  
among activated CD4+ and activated CD8+ T cells. In fact we found 6.5% of cell expressing 
HLAG in CD8+ cells, 26.8% of cell expressing HLAG in CD8+ activated with PHA, 25% of cell 
expressing HLAG with NGAL 40 ng/mL, 32.6% of cell expressing HLAG with NGAL 80 ng/mL, 
33.3% of cell expressing HLAG with NGAL 160 ng/mL, 35% of cell expressing HLAG with 
NGAL 320 ng/mL in subject 4 and 3.7% of cell expressing HLAG in CD8+cells, 19.5% of cell 
expressing HLAG in CD8+ activated with PHA, 24.9% of cell expressing HLAG with NGAL 40 
ng/mL, 33.5% of cell expressing HLAG with NGAL 80 ng/mL, 34.2% of cell expressing HLAG 
with NGAL 160 ng/mL, 34.5% of cell expressing HLAG with NGAL 320 ng/mL in subject 5. 
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Fig. 4 HLA-G expression as fluorescence intensity percentage on CD4+ T cells in control and treated groups after 
treatment with NGAL (40-320 ng\ml). 
 
4.3 NGAL:Enterobactin Iron Free effect on HLA-G expression. 
We also used the complex NGAL:enterocalin iron free to verify if cells response to NGAL was iron 
dependent.  
In PBMCs activated with PHA and treated with NGAL:Enterobactin Iron-free 40 ng/ml (g) an 
increase in HLA-G expression was observed, also if not of the same concentration of 
NGAL:Enterobactin:Iron complex. (Fig.xx). This was true both for CD4+ and for CD8+:36.7% and 
31.3 % for subject 4 and 37.9% and 17.2 % for subject 5 respectively.  
4.4 NGAL:Enterobactin:Iron effect on HLA-G expression following anti-NGAL antibody in vitro 
administration. 
To asses NGAL action inhibition we used anti-NGAL Monoclonal Antibody (200 μg; 1 mg/ml) 
(Thermo Scientific). We found the following values of fluorescence positivity :: 1.7% in PBMCs, 
13.6% in PBMCs+PHA, 28.4 % in PBMCs+PHA+NGAL:Fe 40 ng/ml, 22.2% in 
PBMCs+PHA+NGAL:Fe 40 ng/ml + anti-NGAL, 39.9% in PBMCs+PHA+NGAL:Fe 80 ng/ml and 
18.5 % PBMCs+PHA+NGAL:Fe 80 ng/ml + anti-NGAL.  
We can also observe that the monoclonal antibody action was dose-dependent with an inhibitory 
response more accentuated for 100 ng/mL addiction that for 50 ng/mL addiction  (Figure 5 and 6). 
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Fig. 5 HLA-G expression on PHA activated PBMCs after treatment with NGAL 40 and 80 ng/ml (black 
histogram)  and incubation with an anti-Ngal antibody (white histogram). 
 
Fig. 6 HLA-G expression on PBMCs PHA activated after stimulation with NGAL 40 and 80 ng/ml and 
incubation with an anti-Ngal antibody. 
4.5 Indirect evaluation of NGAL role on HLA-G expression after treatment with Enterobactin:Iron.  
Evaluation of Enterobactin:Iron 160 ng/ml effect on HLA-G expression shows that 
































Figure 7: sHLAG values.  
 
4.6 Soluble HLA-G evaluation trough ELISA after NGAL:Enterobactin:Iron treatment.  
Soluble HLA-G evaluation trough ELISA after NGAL:Enterobactin:Iron treatment shows 
increasing HLA-G secretion dose dependent up to NGAL:Enterobactin:Iron 80 ng/ml. In samples 
treated with NGAL:Enterobactin:Iron 160 and 320 ng/ml secretion of soluble HLA-G decreases. 
Stimulation with NGAL:Enterobactin 40 ng/ml induces HLA-G secretion only higher than the 
control.   
 
4,7 NGAL effect on T regulatory cells 
We wanted also to evaluate NGAL action on CD4+ CD25+ Foxp3+ (regulatory t cells, Tregs) to 
evaluate another important aspect of immune tolerance induction.  
So we analyzed CD4+ FoxP3+ and CD4+ CD25+ FoxP3+ concentration before and after NGAL 
addiction atincreasing dose and with or without iron presence (40 ng/ml with or without iron, 80 
ng/ml, 160 ng/ml, 320 ng/ml). All data about Cd4+FoxP3+ cells and CD4+/CD25+/FoxP3+ cells 
are reported in (figure 8). 
We observed an increase in CD4+ FoxP3+ and CD4+ CD25+ FoxP3+ expression after NGAL 
addiction. This raise was dose and iron and dependent.  
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Indeed the percentage of Tregs increased with growing NGAL doses getting a plateau with 
NGAL:Enterochelin:Iron 320 ng/ml.  The lack of iron did not increased Tregs cells expression.  
Comparing CD4+ and CD25+ cells FoxP3 expression confirmed a dose-dependent raise for the 
treatment with NGAL (40-80-160-320ng/ml). The iron-free NGAL treatment presented less 
increased  expression of Tregs. 
We then verified NGAL direct activity in Tregs expression adding  NGAL antibody and we 
observed that the presence of increasing anti-NGAL antibody determinate a significant reduction of 
Tregs percentage (both CD4+/FoxP3+ and CD4+/CD25+/FoxP3+ .  
Finally we evaluated  NGAL effect on Tregs  expression after Enterobactin:Fe 160 ng/ml treatment 
and we found that Enterobactin:Fe had none effect on CD4+/FoxP3+ and CD4+/CD25+/FoxP3+ 
cells expression  
 

























 cells after treatment of PBMCs with NGAL (40 ng/ml with or without iron, 80 
ng/ml, 160 ng/ml, 320 ng/ml). 
  
5. Discussion and Conclusions 
Nowadays NGAL is emerging as a mediator of various physiological and pathological conditions. 
Indeed in literature is widely documented as NGAL is involved in the transport and metabolism of 
iron, as well as its bacteriostatic activity is well known. The presence of NGAL molecule is also 
important as growth factor and in the differentiation of immature kidney. In the last years 
researchers' attention was focused on the role of NGAL as a biomarker of many diseases including 
acute and chronic kidney damage, kidney transplantation, autoimmune and neoplastic disorders. 
(Chakraborty) 
Despite numerous studies that have investigated the physiological and pathophysiological role of 
NGAL, this is not entirely elucidated. The use as biomarkers in many pathological conditions 
shows that the molecule is characterized by a low specificity for pathology: this leads us to think 
that there is a biological effect of the molecule that is common to these differents pathological 
conditions [157].  
In the light of pathologies involved, the molecule seems to be a response to different pathological 
conditions that are united by inflammation and oxidative stress. [158].   
With regard to the involvement of NGAL in immunity, only one study in the literature verifies the 
involvement in cellular one [159],  while none analyzes the role of the molecule in the humoral one.  
In recent years, the interaction between NGAL and NF-kB (nuclear factor-κB) has been studied. 
The expression of NGAL mRNA and protein is up-regulated in an NF-kB dependent manner in rat 
and human vascular smooth muscle cells (SMCs) in response to IL-1β stimulation [160]. 
Recent evidence showed that there is also a possible interaction between NF-kB and NGAL gene 
requiring  IκB-ζ for its induction: the coexpression of IκB-ζ and the NF-κB subunits synergistically 
activates the transcription of  NGAL genes [161]. The transcription factor NF-κB plays a key role in 
 36 
the innate and adaptive immune systems. The interaction between NGAL and NF-Κb and the 
involvement of NF-κB in innate and adaptative immune system suggest a possible role of NGAL in 
immune tolerance. 
Our study on healthy controls had the aim to individuate the possible involvement of NGAL in the 
processes of immune response, focusing on the hypothesis that NGAL could promote immune 
tolerannce.  
By flow cytometry analysis we demonstrated that NGAL can increase the expression of mHLA-G 
in PBMNCs cell cultures , particularly  for CD4+ T lymphocytes. It is known as the role of HLA-g 
is not only important for the maternal-fetal tolerance. He plays a significant role in adult life and 
especially in some pathological conditions of Autoimmunity, cancer and tolerance in organ 
transplantation [162].  As a factor able of activating the expression of HLA-G,  NGAL may play the 
role of mediator in acute and chronic processes with a similar anti-inflammatory meaning [163].   
We also have shown  that increasing NGAL concentration  raises in vitro level of  mHLA-G . So 
we can postulate that NGAL increasing is not a random process, but it may express a biological 
meaning in various pathological conditions and be modulated in favor of biological necessity. We 
can also indirectly hypnotize that a decreased capability of  NGAL production could be translated  
in a lower reaction to inflammation and aging conditions. 
 The iron absence seems to have a role in  NGAL action, leaving the expression of mHLA-G 
unaltered. The iron deficiency may be negative not only for characterizing systemic inflammation 
states by affecting the anemia conditions, but also inducing aging process and reducing tissue 
renewal [164].  
Use of NGAL:Ent:Fe in the presence anti-NGAL antibody is not able to modify the expression of 
mHLA-G, confirming the action of NGAL molecule on mHLA-G activation.  
Using of increasing concentration of NGAL conjugated with iron induces an activation of Tregs 
cells. The trend of activation seems to depend from NGAL dosing.  
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NGAL role in  FoxP3+ cells activation must be considered with extreme attention in the light of 
Tregs function in autoimmune and neoplastic  disease[165], and in the graft tolerance in solid organ 
transplantation. Several authors indeed proposed Tregs cell therapy for graft tolerance induction. 
In conclusion we believe NGAL is an extremely interesting molecule and its biological role is still 
far from being fully clarified. If clinically most study in recent literature have focused on its role of 
biomarker of kidney , neoplastic and inflammatory diseases we believe that other clinical interest 
scenarios are possible. 
These include the deep understanding of the role of NGAL in humoral immunity may lead not only 
to the understanding of concerning physiopathological mechanisms  but also a molecule used for 
therapeutic purposes in many conditions under which the regulation of immune processes can play 
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